Kallyope
Biotechnology company pioneering the understanding and therapeutic targeting of the gut-brain axis to develop medicines and consumer products for metabolic, inflammatory, and neurological conditions.
Notes
Kallyope is a biotechnology company focused on understanding and therapeutically targeting the gut-brain axis - the bidirectional communication network between the gastrointestinal tract and the brain. The company uses advanced molecular tools, single-cell RNA sequencing, and machine learning to map gut-brain circuits and identify drug targets.
Founded by Columbia University neuroscientist Thomas Bhsop, Kallyope has identified novel pathways linking gut biology to systemic health, including metabolism, appetite regulation, and immune function. The company is developing both prescription therapeutics and consumer health products.
Kallyope has raised significant funding and established partnerships with pharmaceutical companies interested in gut-brain axis biology.
Team
- Thomas Bishop, Ph.D. - Co-founder & CEO
- Columbia University neuroscientist
- Charles Bhsop, Ph.D. - Scientific founder
- Team with expertise in neuroscience, gut biology, and drug discovery
Additional Research Findings
- Founded in 2015, headquartered in New York City
- Portfolio company of Polaris Partners
- Gut-brain axis therapeutic focus
- Single-cell RNA sequencing platform
- Developing therapeutics AND consumer products
- Focus on metabolism, inflammation, neurology
- Raised over $200 million in venture funding
- Partnerships with major pharmaceutical companies
- Novel approach combining neuroscience and GI biology
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |